31.31

1.42% -0.45

After Hours: 31.00 -0.31 -0.99%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Financials Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is traded at $31.31, with a volume of 1.96M. It is down -1.42% in the last 24 hours and down -10.03% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Previous Close:

$31.76

Open:

$32

24h Volume:

1.96M

Relative Volume:

0.74

Market Cap:

$3.64B

Revenue:

Net Income/Loss:

$-472.34M

P/E Ratio:

-7.552

EPS:

-4.1459

Net Cash Flow:

$-340.33M

1W Performance:

-3.33%

1M Performance:

-10.03%

6M Performance:

-14.15%

1Y Performance:

+6.17%

1-Day Range:

$30.46

$32.33

1-Week Range:

$28.82

$32.42

52-Week Range:

$22.96

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

858-704-4660

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2026-04-29

Latest SEC Filings

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VKTX Viking Therapeutics Inc	31.31	3.69B	0	-472.34M	-340.33M	-4.1459
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Oct-29-25	Initiated	Canaccord Genuity	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Goldman	Neutral
Feb-13-25	Initiated	Scotiabank	Sector Outperform
Feb-07-25	Initiated	Citigroup	Neutral
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy
Nov-04-24	Reiterated	H.C. Wainwright	Buy
Sep-11-24	Initiated	JP Morgan	Overweight
Jun-27-24	Initiated	Morgan Stanley	Overweight
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-26-24	Reiterated	Oppenheimer	Outperform
Mar-07-24	Initiated	Jefferies	Buy
Feb-28-24	Reiterated	Oppenheimer	Outperform
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

May 05, 2026

Obesity drug pill data and Phase 3 trial details head to ECO 2026 - Stock Titan

May 05, 2026

Viking Therapeutics: Market Betting On Big Upside Through 2030 (NASDAQ:VKTX) - Seeking Alpha

May 05, 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 - Barchart.com

May 05, 2026

Discipline and Rules-Based Execution in VKTX Response - Stock Traders Daily

May 05, 2026

VKTX Q1 earnings miss on higher phase 3 development costs - MSN

May 05, 2026

May 04, 2026

Dark Horse in the Weight-Loss Drug Arena? Viking Therapeutics Has Potential Upside of Over 200% - NAI500

May 04, 2026

Here's exactly why Wall Street thinks Viking Therapeutics stock could soar 207% over the next 12 months - MSN

May 04, 2026

Viking Therapeutics faces timeline risk, but upside could be huge - MSN

May 04, 2026

Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months - The Motley Fool

May 04, 2026

Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port - Benzinga

May 04, 2026

CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $107 - Moomoo

May 04, 2026

Viking Therapeutics Stock Surges on Bold Analyst Call - TipRanks

May 04, 2026

The $30 Stock Wall Street Values at $93? - Bitget

May 04, 2026

Viking Therapeutics: InvestingPro’s overvalued call proved prescient By Investing.com - Investing.com Australia

May 04, 2026